Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Adhesion of Selegiline TDS vs EMSAM®
NCT07571824Phase 1Completed
- Sponsor
- Corium
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selegiline transdermal patch in major depressive disorder (MDD) (4 arms), sponsored by Corium. Primary endpoints: Bioequivalence between test formulation of Selegiline TDS and EMSAM® TDS at 84 hours and Assessment of patch adhesion at 24 hours. Started Mar 2026; status: completed.
02
Drugs
selegiline transdermal patch
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07571824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07571824.